OneMedNet Partners to Combine First-Party Multimodal Clinical Data with Comprehensive Patient-Journey AI Analytics, Expanding Commercial Reach Through 13th Channel Partnership
The partnership adds approximately 25% to OneMedNet’s sales funnel while leaving data sourcing and curation under its control.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OneMedNet (ONMD) signed its 13th channel partnership, enabling an AI-powered healthcare intelligence company to resell its multimodal clinical data. The agreement is its third AI-focused channel partnership and adds approximately 25% to its sales funnel.
The unnamed partner will combine OneMedNet’s U.S.-sourced, de-identified clinical data with its own claims, pharmacy and encounter data covering hundreds of millions of U.S. patient journeys. OneMedNet retains direct control of data sourcing, curation and de-identification. Its network encompasses more than 90 million patient journeys and 270 million studies. The company intends the combined offering to support healthcare AI model training, clinical development, evidence generation, market access, and research on health economics and outcomes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThe partnership adds approximately 25% to OneMedNet’s sales funnel.
- Minor point. Forward-looking: it has not happened yet and may not happen.13th channel agreement, its third AI-focused partnership, enables resale of OneMedNet’s data alongside the partner’s patient-journey assets.
Negative
- None.
Key Figures
- Sales funnel increase
- approximately 25%
- Attributed to the partnership
- Channel partnership count
- 13th
- OneMedNet’s overall channel partnerships
- AI-focused channel partner count
- third
- OneMedNet’s AI-focused channel partners
- Patient journeys
- more than 90 million
- OneMedNet’s iRWD network
- Studies
- 270 million
- OneMedNet’s iRWD network
Historical Context
-
Added a global pharmaceutical intelligence distributor as its 12th channel partner.
-
Named Mediplexus as its 11th partner for U.S. data distribution in Korea and Asia Pacific.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
real-world data technical
health economics and outcomes research (heor) medical
real-world evidence medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement enables an AI-powered healthcare intelligence company to re-sell OneMedNet’s first-party, direct-from-source multimodal Real-World Data in combination with its own longitudinal patient-journey assets, which include broad claims, pharmacy, and encounter coverage
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 13th channel partner agreement. Under the agreement, an AI-powered healthcare intelligence company will re-sell OneMedNet’s U.S.-sourced, de-identified multimodal clinical data in combination with its own comprehensive real-world patient journey assets. As part of the Company’s channel strategy, this is OneMedNet’s third AI-focused channel partner.
This partnership continues the Company’s deliberate strategy of extending commercial reach through established distribution partners in AI and pharmaceutical research while retaining direct control of data sourcing, curation, and de-identification. The agreement follows recent channel agreements, including our partnership with a global provider of pharmaceutical intelligence and data solutions and another with Mediplexus for distribution into Korea and the broader Asia Pacific region.
This new collaboration is designed to give foundational AI and other customers a more complete view of the patient journey by pairing OneMedNet’s first-party, direct-from-source multimodal clinical data spanning longitudinal clinical records including physician notes, labs, imaging, and reports, from a live network of more than 2,300 healthcare partner sites with the partner’s broad coverage of claims, pharmacy, encounters, and related administrative data across hundreds of millions of U.S. patient journeys. The combined offering is intended to support use cases healthcare AI model training, clinical development, real-world evidence generation, market access, health economics and outcomes research (HEOR) that benefit from both administrative breadth and clinical depth. The partnership is already delivering commercial momentum, adding approximately
OneMedNet’s iRWD™ network currently encompasses more than 90 million patient journeys and 270 million studies. Data is sourced directly from healthcare providers rather than intermediaries or secondary markets and is de-identified at the source to regulatory-grade standards.
“Our channel partners continue to choose OneMedNet because the data comes straight from the source,” said Aaron Green, President & CEO of OneMedNet. “First-party, direct-from-source multimodal data gives partners the clinical depth and provenance their customers need. Combining that with a leading platform’s broad patient-journey coverage creates a differentiated offering that neither dataset can deliver alone.”
Partnership Highlights
- Already delivering commercial momentum: adding approximately
25% to OneMedNet’s sales funnel. - Complementary data, not just distribution: The partner’s broad claims, pharmacy, and encounter coverage is paired with OneMedNet’s first-party clinical depth full-fidelity multimodal records, including imaging, sourced directly from providers.
- Third AI-focused channel partner: The agreement is OneMedNet’s 13th channel partnership overall and its third with an AI-focused partner, extending the Company’s established distribution strategy.
- Control retained: OneMedNet retains direct control of data sourcing, curation, and de-identification, with data de-identified at the source to regulatory-grade standards.
- Broad use cases: The combined offering supports healthcare AI model training, clinical development, real-world evidence generation, market access, and HEOR.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the benefits and expected scope of the channel partner agreement, our distribution strategy, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does OneMedNet’s new AI channel partnership cover?
The agreement enables an AI-powered healthcare intelligence company to resell OneMedNet’s U.S.-sourced, de-identified multimodal clinical data alongside its own patient-journey data. The partner’s assets include claims, pharmacy and encounter coverage. OneMedNet retains control of sourcing, curation and de-identification.
How much does the new partnership add to OneMedNet’s sales funnel?
The partnership adds approximately 25% to OneMedNet’s sales funnel.